Vernalis plc (VER) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Vernalis plc (LON:VER) have been given an average recommendation of “Hold” by the five analysts that are presently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is GBX 26.67 ($0.37).

Separately, Numis Securities reaffirmed an “under review” rating on shares of Vernalis in a research note on Wednesday, February 28th.

LON VER remained flat at $GBX 3.43 ($0.05) during mid-day trading on Friday. Vernalis has a twelve month low of GBX 3.32 ($0.05) and a twelve month high of GBX 26.25 ($0.36).

COPYRIGHT VIOLATION NOTICE: “Vernalis plc (VER) Receives Consensus Recommendation of “Hold” from Analysts” was published by WKRB News and is the property of of WKRB News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.wkrb13.com/2018/04/02/vernalis-plc-ver-receives-consensus-recommendation-of-hold-from-analysts.html.

Vernalis Company Profile

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Receive News & Ratings for Vernalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply